Antiviral Activity of Sodium Fusidate and Related Compounds

Acornley, J. E.; Bessell, Christine J.; Bynoe, M. L.; Godtfredsen, W. O.; Knoyle, J. Mary

doi:10.1111/j.1476-5381.1967.tb01992.x

Cited by 12 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite these in vitro findings, sodium fusidate was unsuccessful in preventing coxsackie virus A21 infection in vivo. 88 …”

Section: Drugs Acting On Picornaviridae Virusesmentioning

confidence: 99%

“… In vitro Respiratory syncytial virus [ 162 ] Erythromycin Reducing intercellular adhesion molecule 1 (ICAM-1) In vitro Rhinovirus [ 86 ] Blocking rhinovirus-induced MUC5AC protein over production and blocking rhinovirus-induced p44/42 MAPK activation In vitro Rhinovirus [ 87 ] Fidaxomicin Inhibiting RNA-dependent RNA polymerase In vitro Zika virus [ 21 ] Inhibiting RNA-dependent RNA polymerase In silico SARS-CoV-2 [ 57 ] 1.2. Quinolones Moxifloxacin Acting on viral main protease (Mpro) In silico SARS-CoV-2 [ 58 ] Ofloxacin Inhibiting large tumour antigen (T Ag) helicase activity In vitro Simian virus 40 [ 144 ] Levofloxacin Reducing intercellular adhesion molecule 1 (ICAM-1) and the number of acidic endosomes In vitro Rhinovirus [ 88 ] Inhibiting large tumour antigen (T Ag) helicase activity In vitro BK virus [ 147 ] Ciprofloxacin Decreasing large tumour antigen (T Ag) expression In vitro BK virus [ 141 ] …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery

Abdulaziz¹,

Elhadi²,

ABDALLAH³

et al. 2022

JEP

View full text Add to dashboard Cite

Drug repurposing process aims to identify new uses for the existing drugs to overcome traditional de novo drug discovery and development challenges. At the same time, as viral infections became a serious threat to humans and the viral organism itself has a high ability to mutate genetically, and due to serious adverse effects that result from antiviral drugs, there are crucial needs for the discovery of new antiviral drugs, and to identify new antiviral effects for the exciting approved drugs towards different types of viral infections depending on the observed antiviral activity in preclinical studies or clinical findings is one of the approaches to counter the viral infections problems. This narrative review article summarized mainly the published preclinical studies that evaluated the antiviral activity of drugs that are approved and used mainly as antibacterial, antifungal, antiprotozoal, and anthelmintic drugs, and the preclinical studies included the in silico, in vitro, and in vivo findings, additionally some clinical observations were also included while trying to relate them to the preclinical findings. Finally, the structure used for writing about the antiviral activity of the drugs was according to the families of the viruses used in the studies to form a better image for the target of antiviral activity of different drugs in the different kinds of viruses and to relate between the antiviral activity of the drugs against different strains of viruses within the same viral family.

show abstract

“…Despite these in vitro findings, sodium fusidate was unsuccessful in preventing coxsackie virus A21 infection in vivo. 88 …”

Section: Drugs Acting On Picornaviridae Virusesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery

Abdulaziz¹,

Elhadi²,

ABDALLAH³

et al. 2022

JEP

View full text Add to dashboard Cite

show abstract

“…As early as 1967, the first antiviral research on FA appeared, FA was found to be ineffective against coxsackie A21 or rhinovirus infection, both orally and intranasally, and fifteen derivatives were found to be inactive or toxic (Acornley et al, 1967). There have been several reports regarding the effectiveness of FA toward human immunodeficiency virus (HIV), and the mechanism of action has also been studied.…”

Section: Antiviral Activitymentioning

confidence: 99%

Bioactivities and Structure–Activity Relationships of Fusidic Acid Derivatives: A Review

Long

Zhang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Fusidic acid (FA) is a natural tetracyclic triterpene isolated from fungi, which is clinically used for systemic and local staphylococcal infections, including methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections. FA and its derivatives have been shown to possess a wide range of pharmacological activities, including antibacterial, antimalarial, antituberculosis, anticancer, tumor multidrug resistance reversal, anti-inflammation, antifungal, and antiviral activity in vivo and in vitro. The semisynthesis, structural modification and biological activities of FA derivatives have been extensively studied in recent years. This review summarized the biological activities and structure–activity relationship (SAR) of FA in the last two decades. This summary can prove useful information for drug exploration of FA derivatives.

show abstract

Antiviral activity of triterpenoid saponins containing acylated β-amyrin aglycones

Rao

Sinsheimer²,

Cochran

1974

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Antiviral Activity of Sodium Fusidate and Related Compounds

Cited by 12 publications

References 11 publications

Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery

Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery

Bioactivities and Structure–Activity Relationships of Fusidic Acid Derivatives: A Review

Antiviral activity of triterpenoid saponins containing acylated β-amyrin aglycones

Contact Info

Product

Resources

About